Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Magro

Showing results (191-200 of 340) with videos related to

Pageof 34
Sort By:
Journal of Crohn'S & Colitis|October 18, 2018
Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes-Bayesian Network AnalysisFernando Magro, Cláudia Camila Dias, Francisco Portela, et al.
The Lancet. Gastroenterology & Hepatology|April 9, 2022
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD surveyTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Therapeutic Advances in Gastroenterology|December 7, 2020
Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassaysCátia Rocha, Paula Lago, Samuel Fernandes, et al.
Inflammatory Bowel Diseases|April 4, 2026
Transmural improvement may be an acceptable target in patients with Crohns diseaseSamuel Raimundo Fernandes, Sérgio Bronze, Inês Coelho Rodrigues, et al.
Journal of Crohn'S & Colitis|February 17, 2024
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European ConsensusMassimo Claudio Fantini, Gionata Fiorino, Agostino Colli, et al.
Microorganisms|June 28, 2023
Viable <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> Colonizes Peripheral Blood of Inflammatory Bowel Disease PatientsMaria Manuela Estevinho, José Cabeda, Mafalda Santiago, et al.
Plos One|February 23, 2017
The risk of disabling, surgery and reoperation in Crohn's disease - A decision tree-based approach to prognosisCláudia Camila Dias, Pedro Pereira Rodrigues, Samuel Fernandes, et al.
Journal of Crohn'S & Colitis|April 16, 2013
Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control populationCândida Abreu, Fernando Magro, João Santos-Antunes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 22, 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 TrialFernando Magro, Marijana Protic, Gert De Hertogh, et al.
Inflammatory Bowel Diseases|June 25, 2025
Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched AnalysisSamuel Raimundo Fernandes, Inês Coelho Rodrigues, André Da Silva Neves, et al.
Pageof 34

Showing results (191-200 of 340) with videos related to

Sort By:
Pageof 34
Journal of Crohn'S & Colitis|October 18, 2018
Development and Validation of Risk Matrices Concerning Ulcerative Colitis Outcomes-Bayesian Network AnalysisFernando Magro, Cláudia Camila Dias, Francisco Portela, et al.
The Lancet. Gastroenterology & Hepatology|April 9, 2022
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD surveyTommaso Lorenzo Parigi, Ferdinando D'Amico, Maria T Abreu, et al.
Therapeutic Advances in Gastroenterology|December 7, 2020
Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassaysCátia Rocha, Paula Lago, Samuel Fernandes, et al.
Inflammatory Bowel Diseases|April 4, 2026
Transmural improvement may be an acceptable target in patients with Crohns diseaseSamuel Raimundo Fernandes, Sérgio Bronze, Inês Coelho Rodrigues, et al.
Journal of Crohn'S & Colitis|February 17, 2024
Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European ConsensusMassimo Claudio Fantini, Gionata Fiorino, Agostino Colli, et al.
Microorganisms|June 28, 2023
Viable <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> Colonizes Peripheral Blood of Inflammatory Bowel Disease PatientsMaria Manuela Estevinho, José Cabeda, Mafalda Santiago, et al.
Plos One|February 23, 2017
The risk of disabling, surgery and reoperation in Crohn's disease - A decision tree-based approach to prognosisCláudia Camila Dias, Pedro Pereira Rodrigues, Samuel Fernandes, et al.
Journal of Crohn'S & Colitis|April 16, 2013
Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control populationCândida Abreu, Fernando Magro, João Santos-Antunes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 22, 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 TrialFernando Magro, Marijana Protic, Gert De Hertogh, et al.
Inflammatory Bowel Diseases|June 25, 2025
Early Top-Down Treatment With Biologics Improves the Rates of Transmural Remission in Crohn's Disease-A Risk-Adjusted Propensity Score Matched AnalysisSamuel Raimundo Fernandes, Inês Coelho Rodrigues, André Da Silva Neves, et al.
Pageof 34